Please login to the form below

Not currently logged in
Email:
Password:

Aptalis

This page shows the latest Aptalis news and features for those working in and with pharma, biotech and healthcare.

HIV prevention pill heads July CHMP recommendations

HIV prevention pill heads July CHMP recommendations

Other positive recommendations were given for Aptalis' Truberzi (eluxadoline) as a treatment for irritable bowel syndrome with diarrhoea, along with two biosimilar versions of Sanofi's clot-busting drug Lovenox (enoxaparin) -

Latest news

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals during February 2014 Pharma deals during February 2014

    The deal is expected to close mid 2014, pending approvals. The announcement came just after Forest completed its acquisition of Aptalis last month for $3bn and this month sold a number

  • Pharma deals during January 2014 Pharma deals during January 2014

    Almost right to the end of the month, the big headline deal was that of Forest with its planned takeover of Aptalis. ... Aptalis itself was only formed in 2011 following the acquisition of Eurand by the Montreal based Axcan Pharma.

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    4, 295. Aptalis/ Forest. Company acquisition. Acquiring sales turnover of $688m. 2, 900.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics